Separately, Zacks Investment Research upgraded Galmed Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, February 1st.
NASDAQ GLMD opened at $1.57 on Monday. The firm has a market cap of $39.38 million, a PE ratio of -1.05 and a beta of 1.95. Galmed Pharmaceuticals has a one year low of $1.19 and a one year high of $4.08. The stock’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $2.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.88 and a quick ratio of 6.88.
Galmed Pharmaceuticals Company Profile (Get Rating)
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
- Get a free copy of the StockNews.com research report on Galmed Pharmaceuticals (GLMD)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Greenbrier Companies Stock has Green in its Future
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.